Menu
← Oncology Approval Tracker
FDA DECISION ·
Trodelvy
sacituzumab govitecan-hziy · Immunomedics / Gilead
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with locally advanced or metastatic urothelial carcinoma previously treated with platinum chemotherapy and a PD-1 or PD-L1 inhibitor. FDA withdrew this indication on November 22, 2024.
LAMPGEN ANALYSIS
Why it matters
The accelerated authorization added a distinct urothelial use that was subsequently withdrawn.
What research teams should watch
Keep the historical urothelial action separate from breast cancer uses and record its withdrawal in comparator timelines.
PRIMARY RECORDS